David Ricks, Eli Lilly CEO, weighs in on tax reform priorities, border adjustment tax and drug pricing.
Feb 22- CVS Health Corp said its pharmacy chain had removed artificial trans fats, which have been linked to rising rates of heart diseases, from its store-branded food products well ahead of a June 2018 federal deadline. The U.S. Food and Drug Administration said in June 2015 that PHOs were not "generally recognized as safe" for use in human food and gave food...
CNBC's Jim Cramer and David Faber weigh in on Carl Icahn stepping up the pressure on Bristol-Myers.
Chester Davis, Association for Accessible Medicines CEO weighs in on highly-priced generic drugs.
CNBC's Meg Tirrell reports the latest on how the fight over drug prices has sparked a civil war in the pharmaceutical industry, with big branded companies in one corner and the generics in the other.
Dave Dorman, CVS Health non-excutive chairman and former AT&T chairman & CEO, discusses the issues around drug pricing and pharmaceutical companies.
Discussing the potential downside to pharmaceutical companies developing cures with Dr. Peter Bach, Memorial Sloan Kettering Center for Health Policy, and Brian Skorney, Baird biotechnology analyst. CNBC's Meg Tirrell also weighs in.
CNBC's Meg Tirrell reports on Gilead's new drug that cures Hepatitis C.
Feb 9- Drugstore chain and pharmacy benefits manager CVS Health Corp reported an 11.7 percent rise in quarterly revenue on Thursday, helped by strength in its PBM business. Net income attributable to CVS rose to $1.71 billion, or $1.59 per share, in the fourth quarter ended Dec. 31, from about $1.50 billion, or $1.34 per share, a year earlier. Revenue rose to $45.97...
The new terms set shares of Rite Aid at a maximum of $7 per share and $6.50 minimum, down from the initial $9 Walgreens agreed to purchase.
Novo Nordisk is investing 115 million pounds in a new research center in Britain, undeterred by Brexit.
Shares of Walgreen Boots Alliance and Rite Aid are trading lower after the merger of the two drugstore companies is facing US antitrust concerns.
"Fast Money" trader David Seaburg pitches to the desk why to buy Eli Lilly.
Michael King, JMP Securities senior analyst, weighs in on the biotech sector as President-elect Donald Trump puts the pharmaceutical industry in his cross hairs, calling it "disastrous."
CNBC's Bob Pisani and Art Cashin, of UBS, discuss the market’s reaction to President-elect Donald Trump’s first news conference since Election Day.
*Japan's consumer prices fall for nine straight months. TOKYO, Jan 11- Aeon Co posted a 51 percent jump in its third-quarter operating profit as brisk business at supermarkets, drug stores and discount outlets helped the biggest retailer by sales in Japan offset losses at its general merchandise stores. Operating profit for quarter ended Nov. 30 was 13 billion...
Mylan CEO Heather Bresch speaks to CNBC's Meg Tirrell about the future of EpiPen pricing under President-elect Donald Trump as he pushes to bring drug prices down.
Mylan CEO Heather Bresch speaks to CNBC's Meg Tirrell about the future of EpiPen pricing.
CNBC's Meg Tirrell speaks with Express Scripts President & CEO Tim Wentworth on pharmacy benefit managers and drug pricing pressure.
Valeant CEO Joseph Papa speaks to CNBC's Meg Tirrell about the company's turnaround process and drug price increases.